Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Dec 07, 2020
Notification of investor briefing webinar
Dec 07, 2020
Positive opinion for all 3 Orphan applications in Europe
Nov 19, 2020
Approval received for final stage of NNZ-2591 clinical trial
Oct 29, 2020
Quarterly report and cash flow statement for Q3 2020
Sep 29, 2020
Neuren requests Orphan designations for NNZ-2591 in Europe
Sep 22, 2020
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
Aug 26, 2020
Half-year Shareholder Update
Aug 26, 2020
Half Yearly Report and Accounts
Aug 18, 2020
Corporate presentation, 18 August 2020
Aug 11, 2020
Change of Director's Interest Notice
1
2
3
4
5
6
Next
